- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04240990
Development of a Diagnostic Prediction Score for Tuberculosis in Hospitalized Children With Severe Acute Malnutrition (TB-Speed SAM)
Study Overview
Status
Conditions
Detailed Description
There is now strong evidence that undiagnosed and untreated TB increases the risk of death in children, especially those severely malnourished who are highly vulnerable. Specific decision-making tools are therefore urgently needed to guide clinicians from high TB burden and low-income countries to initiate treatment quickly in children with SAM with suspected TB.
A diagnostic prediction score and algorithm was recently proposed by the investigators for TB treatment decision in HIV-infected children with presumptive TB (developed in the ANRS 12229 PAANTHER 01 study). Based on easily collected clinical features, chest X-Ray (CXR), Xpert MTB/RIF, and abdominal ultrasonography, the score aims to help clinicians make a same-day treatment decision. Such a prediction score improving TB diagnosis and shortening time to treatment initiation would be a key benefit in children with SAM.
Based on this experience, the investigators are proposing a diagnostic cohort study enrolling hospitalized severely malnourished children. The study will include the evaluation of several diagnostic tests that could be integrated in the development of a prediction model and subsequent score for the diagnosis of TB in hospitalized children with SAM. This will include Xpert MTB/RIF Ultra performed on one nasopharyngeal aspirate (NPA) and one stool sample, CXR, Quantiferon (QFT) Interferon-Gamma Release Assay (IGRA), Monocyte-to-lymphocyte ratio (MLR), and ultrasonography, which has shown its interest for the diagnosis of TB in both HIV-infected adults and children. In the PAANTHER study, it detected abdominal lymphadenopathy in 50% of culture confirmed TB cases and 35% of all confirmed and unconfirmed cases, with a specificity of 85%.
Using logistic regression, a score will be developed for TB diagnosis, considering confirmed and unconfirmed TB as reference diagnosis, in hospitalized children with SAM. As a secondary objective, and in order to reduce costs, sample collection, and complexity of the diagnostic process, a first-step screening score (excluding Ultra, abdominal ultrasound, and CXR if possible) will be developed to identify children with presumptive TB who would benefit from further diagnostic testing.
Both scores will be internally validated using resampling and will be incorporated in a stepwise algorithm to guide practical implementation of the screening and diagnosis process. The stepwise algorithm will be discussed with local clinicians involved in the study to better adapt it for future use in their routine practice.
The study will be implemented at inpatient nutrition centres from three selected tertiary hospitals in Uganda, and Zambia. A total of 720 children <5 years old with WHO-defined severe acute malnutrition will be enrolled with an equal distribution between sites, that is 240 participants per hospital.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Kampala, Uganda
- Recruiting
- Mulago National Referral Hospital
-
Contact:
- Country Principal Investigator
- Email: ewobudeya@mujhu.org
-
Contact:
- Country co-Principal Investigator
- Email: Juliet.MWANGA@epicentre.msf.org
-
-
-
-
-
Lusaka, Zambia
- Recruiting
- Lusaka University Teaching Hospital
-
Ndola, Zambia
- Not yet recruiting
- Arthur Davidson Children Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Children aged < 5 years
- Severe acute malnutrition defined as weight-for-height Z score (WHZ) < -3 standard deviation (SD) or mid-upper arm circumference (MUAC) < 115 mm or clinical signs of bilateral pitting oedema in children aged <5 years [2]
- Hospitalized per hospital clinician's decision
- Parent/guardian informed consent
Exclusion Criteria:
- Ongoing TB treatment or history of intake of anti-TB drugs in the last 3 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Prospective cohort
Children included in the cohort will all be in the same arm.
The patients will benefit from standard-of-care TB diagnosis with additional diagnostic methods.
|
The diagnostic strategy will include an initial clinical, radiographic and bacteriological evaluation of all enrolled children:
TB diagnosis will be made according to national TB guidelines. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sensitivity of the score obtained
Time Frame: 6 months
|
Sensitivity of the score obtained using predicted probability cut-off with the prediction model for the diagnosis of TB, defined as either confirmed or unconfirmed using the updated Clinical Case Definition for Classification of Intrathoracic Tuberculosis
|
6 months
|
Specificity of the score obtained
Time Frame: 6 months
|
Specificity of the score obtained using predicted probability cut-off with the prediction model for the diagnosis of TB
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of children with NPA and stool samples collected as per study protocol
Time Frame: 6 months
|
Feasibility of NPA and stool samples collection in HIV-infected children defined as the proportion of children with NPA and stool samples collected as per study protocol
|
6 months
|
Proportion of NPA-related adverse events (AEs)
Time Frame: 6 months
|
Safety of NPA collection defined as proportion of AEs (vomiting, nose bleeding, low oxygen saturation, respiratory distress) occurring during NPA
|
6 months
|
Prevalence of TB among hospitalized children with SAM
Time Frame: 6 months
|
Proportion of confirmed and unconfirmed TB in the study population
|
6 months
|
Clinical characteristics of TB disease in hospitalized children with SAM
Time Frame: 6 months
|
Signs and symptoms of children with tuberculosis (confirmed and unconfirmed)
|
6 months
|
Bacteriological characteristics of TB disease in hospitalized children with SAM
Time Frame: 6 months
|
Bacteriological characteristics (mycobacterial culture and drug susceptibility testing) of children with tuberculosis (confirmed and unconfirmed)
|
6 months
|
Biological characteristics of TB disease in hospitalized children with SAM
Time Frame: 6 months
|
Haematological and immunological characteristics (full blood count, transaminases, CRP, IFN gamma) of children with tuberculosis (confirmed and unconfirmed)
|
6 months
|
Radiological characteristics of TB disease in hospitalized children with SAM
Time Frame: 6 months
|
Radiological features (chest X-ray and abdominal US) of children with tuberculosis (confirmed and unconfirmed)
|
6 months
|
Estimated time to TB treatment decision in hospitalized children with SAM
Time Frame: 6 months
|
Estimated time to TB treatment decision in hospitalized children with SAM, with and without presumptive TB based on the first-step screening prediction score
|
6 months
|
Diagnostic accuracy measures: 1/ Sensitivity of the different tests evaluated for the diagnosis of TB
Time Frame: 6 months
|
Sensitivity of the different tests evaluated for the diagnosis of TB (Ultra performed on NPA and stools, CXR, abdominal ultrasound, QFT, MLR, CRP
|
6 months
|
Diagnostic accuracy measures: 2/ Specificity of the different tests evaluated for the diagnosis of TB
Time Frame: 6 months
|
Specificity of the different tests evaluated for the diagnosis of TB (Ultra performed on NPA and stools, CXR, abdominal ultrasound, QFT, MLR, CRP
|
6 months
|
Diagnostic accuracy measures: 3/ Negative predictive value of the different tests evaluated for the diagnosis of TB
Time Frame: 6 months
|
Negative predictive value of the different tests evaluated for the diagnosis of TB (Ultra performed on NPA and stools, CXR, abdominal ultrasound, QFT, MLR, CRP
|
6 months
|
Diagnostic accuracy measures: 4/ Positive predictive value of the different tests evaluated for the diagnosis of TB
Time Frame: 6 months
|
Positive predictive value of the different tests evaluated for the diagnosis of TB (Ultra performed on NPA and stools, CXR, abdominal ultrasound, QFT, MLR, CRP)
|
6 months
|
Diagnostic accuracy measures: 5/ AUROC of diagnostic prediction models with and without the different tests results
Time Frame: 6 months
|
Area Under the Receiver Operating Characteristics curve
|
6 months
|
Diagnostic accuracy of Ultra performed on one NPA and one stool sample against mycobacterial culture performed on gastric aspirates
Time Frame: 6 months
|
Proportion of NPAs and stool samples with mycobacterium tuberculosis detected using Ultra
|
6 months
|
Tolerability of NPA collection: 1/ Discomfort/pain/distress experienced by the child as assessed by the child
Time Frame: Within 3 days of inclusion
|
Discomfort/pain/distress experienced by the child during NPA collection, as assessed by the child using the Wong-Baker face scale (in a subset of children). Scale range: 0 (no hurt) - 5 (hurts worst) |
Within 3 days of inclusion
|
Tolerability of NPA collection: 2/ Discomfort/pain/distress experienced by the child as assessed by the parents
Time Frame: Within 3 days of inclusion
|
Discomfort/pain/distress experienced by the child during NPA collection, as assessed by the parents using the visual analog scale (in a subset of children). Scale range: 0 (no pain) - 10 (pain as bad as it could possibly be) |
Within 3 days of inclusion
|
Tolerability of NPA collection: 3/ Discomfort/pain/distress experienced by the child as assessed by the nurse
Time Frame: Within 3 days of inclusion
|
Discomfort/pain/distress experienced by the child during NPA collection, as assessed by the nurses using the "Face Legs Activity Cry Consolability" behavioral pain scale (in a subset of children). Total score range: 0 (relaxed and comfortable) - 10 (severe discomfort/pain). Each item of the FLACC scale - Face, Legs, Activity, Cry, Consolability - has 3 possible quotes: 0 or 1 or 2, with a precise description provided to help with the rating. The total score is obtained by adding individual item scores. |
Within 3 days of inclusion
|
Mortality at 6 months
Time Frame: 6 months
|
Mortality at 6 months in children with SAM, with or without TB treatment
|
6 months
|
Percentage weight gain 6 months
Time Frame: 6 months
|
Weight gain and WHZ at 6 months in children with SAM, with or without anti-TB treatment
|
6 months
|
TB treatment outcomes
Time Frame: 6 months
|
TB treatment outcomes as defined per WHO guidelines (Cured, Treatment completed, Treatment failed, Died, Lost to follow-up, Not evaluated, Treatment success)
|
6 months
|
Collaborators and Investigators
Collaborators
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- C18-28
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tuberculosis
-
Global Alliance for TB Drug DevelopmentCompletedTuberculosis | Tuberculosis, Pulmonary | Pulmonary Disease | Multi Drug Resistant Tuberculosis | Drug Sensitive Tuberculosis | Drug-resistant Tuberculosis | Mycobacterium Tuberculosis InfectionUnited States
-
Global Alliance for TB Drug DevelopmentCompletedTuberculosis | Tuberculosis, Pulmonary | Pulmonary Disease | Multi Drug Resistant Tuberculosis | Drug Sensitive Tuberculosis | Drug-resistant Tuberculosis | Mycobacterium Tuberculosis InfectionUnited States
-
University of Cape TownUniversity of Stellenbosch; University of Cape Town Lung Institute; University... and other collaboratorsCompletedTuberculosis | Multidrug Resistant Tuberculosis | Extensively-drug Resistant TuberculosisSouth Africa
-
Universiteit AntwerpenAurum Institute; University of Stellenbosch; University of the Free State; Free...RecruitingDrug-resistant Tuberculosis | Rifampicin Resistant Tuberculosis | Pulmonary Tuberculoses | Multidrug Resistant TuberculosisSouth Africa
-
Assistance Publique - Hôpitaux de ParisCompletedExtrapulmonary Tuberculosis | Lymph Node Tuberculosis | Bone TuberculosisFrance
-
Centers for Disease Control and PreventionBoston University; Pfizer; Columbia University; University of Texas; University of... and other collaboratorsCompletedMulti-Drug Resistant Tuberculosis | Extensively Drug Resistant TuberculosisSouth Africa
-
University Medical Center GroningenCompletedMultidrug-resistant Tuberculosis | Extensively Drug-resistant TuberculosisNetherlands
-
Foundation for Innovative New Diagnostics, SwitzerlandInstitute of Tropical Medicine, Belgium; Research Center Borstel; National Institute...CompletedMultidrug-Resistant Tuberculosis | Isoniazid Resistant Pulmonary Tuberculosis | Rifampicin Resistant Tuberculosis | Pulmonary Tuberculoses
-
National Institute of Allergy and Infectious Diseases...CompletedPulmonary Tuberculosis | Multidrug Resistant Tuberculosis | Extensively Drug Resistant TuberculosisKorea, Republic of
-
Wits Health Consortium (Pty) LtdUniversity of Cape Town; Perinatal HIV Research Unit of the University of the... and other collaboratorsActive, not recruitingTuberculosis | Multi Drug Resistant Tuberculosis | Rifampicin Resistant Tuberculosis | Extensively Drug-Resistant Tuberculosis | Pre-XDR-TBSouth Africa
Clinical Trials on Development of a score and algorithm for TB treatment decision in hospitalised children with SAM.
-
University of South FloridaUniversity of MiamiUnknownMisophoniaUnited States
-
University Hospital, RouenNot yet recruiting
-
University of BolognaAzienda Ospedaliera Universitaria Policlinico Paolo GiacconeNot yet recruitingCancer Related Cardiovascular ToxicityItaly, North Macedonia, Serbia
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...Enrolling by invitationHIV Infections | Opioid Use | Drug Use | Opioid-use DisorderUnited States
-
Assiut UniversityNot yet recruitingAdolescents | Psychiatric Disorders | Diabetes Mellitus Type 1
-
Case Comprehensive Cancer CenterTerminatedAny Cancer DiagnosisUnited States
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingConfirmed Diagnosis of ß-thalassemia MajorUnited States
-
Memorial Sloan Kettering Cancer CenterTufts Medical Center; Lahey ClinicCompleted
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedNeuroblastomaUnited States
-
Memorial Sloan Kettering Cancer CenterPfizer; Dana-Farber Cancer Institute; University of Pittsburgh; University of VirginiaCompletedNeurofibromatosis | Meningioma | CNS Cancer | Hemangioblastoma | Intracranial HemangiopericytomaUnited States